Navigation Links
A search for biomarkers for early detection of colorectal cancer
Date:9/24/2007

Researchers at the Zhejiang University, Hangzhou have discovered that mimecan and Thioredoxin Domain-Containing Protein 5 (TXNDC5) were differentially expressed in colorectal adenoma. The research article describing this work entitled Differential Expression of Mimecan and Thioredoxin Domain-Containing Protein 5 in Colorectal Adenoma and Cancer: A Proteomic Study will be featured in the October 2007 issue of Experimental Biology and Medicine.

Adenoma is the major precursor lesion of colorectal cancer, one of the most common cancers worldwide. The elucidation of the molecular mechanism underlying adenoma is essential for early detection, prevention and intervention of colorectal cancer.

The research team, led by Maode Lai, a professor of molecular pathology, found 27 differentially expressed proteins in colorectal adenoma using two dimensional electrophoresis (2-DE) and mass spectrometry. Western-blot analysis clearly validated 2 differentially expressed proteins, mimecan downregulation and TXNDC5 upregulation in colorectal adenomas and cancers.

Adenoma is a very important step in the development of cancer. Discovering the biomarker of adenoma will improve the early detection and prevention of cancer, said Lai. 2-DE is an efficient traditional approach for the identification of differentially expressed proteins in cancer biology. Using this technology, we first identified 27 differentially expressed proteins in individual-matched colorectal normal, adenoma and cancer tissues.

This study found two novel proteins which have never been found to be associated with colorectal cancer. We clearly demonstrated that absence of mimecan and up-regulation of TXNDC5 were involved in the early development of colorectal cancer, said the articles first author Yinghong Wang. Our further work showed that mimecan can inhibit cell growth and induce cell apoptosis in colorectal cancer cells implying a candidate role as a tumor suppressor gene for the mimecan gene. These results suggested that mimecan might serve as a potential biomarker for future gene therapy.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said Lai and his colleagues have performed a protein profiling proteomic study to understand the molecular mechanisms leading to colorectal cancer. It is this type of approach which can lead to the identification of biomarkers for the early detection of colorectal cancer, and targets for future gene therapy.


'/>"/>

Contact: Dr. Maode Lai
lmp@zju.edu.cn
86-571-882-08198
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
3. Columbia research lifts major hurdle to gene therapy for cancer
4. Researchers find how protein allows insects to detect and respond to pheromones
5. Researchers Uncover Key Step In Manufacture of Memory Protein
6. Research advances quest for HIV-1 vaccine
7. Research on Worms Yields Clues on Aging
8. U of M researcher examines newly emerging deadly disease
9. NYU researchers simulate molecular biological clock
10. Researchers reveal the infectious impact of salmon farms on wild salmon
11. Researchers identify target for cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 MedNet ... that supports the entire spectrum of clinical research, ... another record-breaking year for the organization in terms ... in MedNet,s eClinical products and services. The company,s ... marketplace success of iMedNet ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market is ... 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  An international ... of Medicine and St. Boniface Hospital Albrechtsen Research ... peripheral neuropathy, an unmet health need affecting nearly ... Journal of Clinical Investigation, their results identify small ... prevent and reverse neuronal injury in animal models ...
(Date:1/17/2017)... LEXINGTON, Mass. , Jan. 17, 2017   ... clinical stage biopharmaceutical company developing innovative inhaled therapies to ... candidate for treating fungal infections in the lungs of ... Infectious Disease Product" (QIDP) by the U.S. Food & ... , which is designed to speed the development of ...
(Date:1/17/2017)... 17, 2017  Only nine percent of U.S. consumers ... while only 16 percent believe health insurance companies do, ... 36 percent of U.S. adults believe health care providers ... compared to hospitals (23%). "We are in ... Wendy Salomon , vice president of reputation management and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a mind-body wellness firm ... today the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue ... development for over a year, the patented Pono Board is the world’s only exercise ...
Breaking Biology Technology: